Physician profile
Bryan D Mcdonnell
NPI 1710996517
$3,483.89
in general payments reported to CMS, 2019-2025
34 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $291 · 2021: $349 · 2022: $594 · 2023: $680 · 2024: $606 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.39 | 2021-2025 | |
| Pfizer INC. | $399.80 | 2019-2025 | |
| Lilly USA, LLC | $374.81 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $366.44 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $292.86 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $243.83 | 2019-2024 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals Lp | $172.85 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $125.05 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $116.08 | 2019-2024 | Veozah |
| Novo Nordisk INC | $115.88 | 2019-2022 | |
| Allergan, INC. | $90.16 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $82.93 | 2019-2025 | Gardasil 9, Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.82 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.81 | 2022-2025 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $56.20 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.06 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $49.10 | 2021-2022 | |
| Exact Sciences Corporation | $47.82 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $41.23 | 2022-2023 | |
| Abiomed | $38.88 | 2025 | |
| Esperion Therapeutics, INC. | $28.52 | 2021-2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $25.28 | 2021 | |
| Antares Pharma, INC. | $16.18 | 2025 | Xyosted |
| Otsuka America Pharmaceutical, INC. | $16.14 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $15.65 | 2022 | |
| Bausch Health US, LLC | $15.51 | 2022 | |
| Pacira Therapeutics, INC. | $14.56 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.66 | 2020 | |
| Shield Therapeutics INC | $13.43 | 2023 | Accrufer |
| Almatica Pharma LLC | $12.94 | 2022 | |
| Genentech USA, INC. | $12.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.32 | 2020 | |
| Sanofi Pasteur INC. | $10.98 | 2019 | |
| Kinex Medical Company LLC | $4.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Mcdonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.